Healthcare

Healthcare sector stocks including pharmaceuticals, biotechnology, and medical devices.

63 articles

Healthcare | LLY | 2w ago

LLY Soars on Legal Developments Surrounding Weight-Loss Competitor

LLY experiences a surge as legal concerns mount around competitor Hims offering a low-cost version of a competing product. Find out more.

Healthcare | LLY | 2w ago

Eli Lilly's Board Shakeup: What It Means for LLY Investors

LLY faces a significant shift as two board members exit. This analysis explores the implications for Eli Lilly shareholders.

Healthcare | VRTX | 2w ago

Vertex Pharmaceuticals Eyes New Highs After Q4 Earnings Surprise

VRTX's Q4 earnings missed expectations, yet revenue exceeded forecasts, highlighting strong CF sales and new product momentum.

Healthcare | VRTX | 2w ago

Analyst Take: Vertex Pharmaceuticals Posts Strong Q4 2025 Earnings

VRTX's Q4 2025 earnings beat expectations, raising questions about future growth. Discover the implications for Vertex Pharmaceuticals and investors.

Healthcare | VRTX | 2w ago

Vertex Pharmaceuticals Surprises Wall Street With Strong Q4 Metrics

VRTX posted surprising Q4 results that exceeded analyst expectations, showcasing strong financial performance. Here’s what that means for investors.

Healthcare | NVO | 2w ago

Novo Nordisk Gains Steam After Legal Action Against Hims & Hers

NVO's recent legal action against Hims & Hers highlights growing regulatory scrutiny in the obesity treatment market, impacting investor sentiment.

Healthcare | NVO | 2w ago

Novo Nordisk Stands Out Among Peers After Strong Q4 Earnings Beat

NVO shares surged following a robust Q4 earnings report, highlighting significant revenue growth. Investors are optimistic about Novo Nordisk's future.

Healthcare | RPRX | 2w ago

Royalty Pharma's Revenue Surge: Vertex's Milestones Set the Tone

Royalty Pharma (RPRX) stands to gain from Vertex Pharmaceuticals' significant revenue growth in cystic fibrosis therapies. Discover the financial implications.

Healthcare | NVO | 2w ago